Tinidazole
Mostrando 1-12 de 42 artigos, teses e dissertações.
-
1. Atividade anti-trichomonas vaginalis de moléculas produzidas por basidiomicetos
The flagellated protozoan, Trichomonas vaginalis, causes trichomonosis, the most common non-viral sexual transmitted disease (STD) in the world. Metronidazole and tinidazole are two drugs of choice recommended by Food and Drug Administration (FDA, USA) for treatment of human trichomonosis. However, clinical or laboratory-generated drug-resistant isolates of
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 2011
-
2. Efeito da utilização de culturas láticas probióticas na microbiota vaginal de pacientes acometidas por infecções bacterianas e fúngicas / Effect of lactic acid probiotic cultures utilization on the vaginal microbiota of women diagnosed with bacterial and fungal infections
A microbiota vaginal saudável é constituída, majoritariamente, por espécies de lactobacilos que representam uma barreira natural contra microrganismos causadores de doenças como a candidíase vulvovaginal (CVV), vaginose bacteriana (VB) e infecções do trato urinário (ITU), que juntas acometem cerca de um bilhão de mulheres no mundo anualmente. Um me
Publicado em: 2008
-
3. Bioequivalence evaluation of tinidazole 500 mg tablets / Avaliação de bioequivalência de comprimidos contendo 500 mg de tinidazol
Tinidazole, 1-[2-(ethylsulphonyl)ethyl]-2-methyl-5-nitroimidazole, is a member of the 5-nitroimidazole class of antimicrobial agents with amoebicidal, giardicidal, trichomonicidal and anaerobic activity. The purpose of this study was to evaluate the bioequivalence of two brands of tinidazole 500mg tablets in healthy human volunteers. The procedure of bioequi
Publicado em: 2005
-
4. In Vitro Metronidazole and Tinidazole Activities against Metronidazole- Resistant Strains of Trichomonas vaginalis
The in vitro activities of tinidazole and metronidazole against Trichomonas vaginalis isolates clinically resistant to metronidazole were compared. Minimal lethal concentrations (MLCs) of tinidazole were significantly lower than MLCs of metronidazole. Increased metronidazole resistance correlated with increased tinidazole resistance. These data support a rol
American Society for Microbiology.
-
5. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses.
Serum concentrations of tinidazole and metronidazole have been measured in healthy female volunteers who received a single dose of 2 g. of each drug in a cross-over study. Bioassays against T. vaginalis showed that metronidazole achieved higher peak concentrations (mean 81 mug./ml.) than did tinidazole (mean 67 mug./ml.), while assays for unchanged drug show
-
6. Single-dose tinidazole for the treatment of giardiasis.
Sixty-three expatriate residents and travellers in Bangladesh, infected with Giardia lamblia, participated in two studies to compare the therapeutic efficacy of tinidazole and metronidazole. In the first trial 33 randomly selected patients were treated with tinidazole (50 mg/kg of body weight to a maximum of 2 g) or metronidazole (60 mg/kg of body weight to
-
7. Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women.
A comparison is made between oral ornidazole in a single 1-5 g dose and tinidazole given in a 2 g dose using a double-blind technique. All the 45 women with Trichomonas vaginalis infection who were treated with ornidazole were cured. In the tinidazole-treated group 41 out of 43 women had negative cultures after treatment. Tolerance was good in both groups.
-
8. Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius.
Broth dilution MICs of metronidazole against 38 strains of Clostridium difficile (0.13 microgram/ml) and 11 strains of Peptostreptococcus anaerobius (0.11 microgram/ml) were lower than those of tinidazole (0.16 and 0.17 microgram/ml, respectively). As molar concentrations the nitroimidazoles were equally active. The MICs of the two drugs correlated positivel
-
9. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.
Serum kinetics of metronidazole and tinidazole were compared in four separate randomized crossover studies. Single doses of each drug were given to healthy volunteers through intravenous infusion (500 mg over 20 min, six persons), by mouth (500 mg, nine persons), by rectum (1,000 mg, six persons), or intravaginally (500 mg, six persons). Concentrations of th
-
10. Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects.
We developed methods for measuring metronidazole, its two major metabolites, and tinidazole in serum and urine. After treatment of each sample with an equal volume of 5% perchloric acid, the drugs were separated by reverse-phase high-pressure liquid chromatography (retention times, 6 to 18 min). Quantitation was based on spectrometry at 320 nm. These assays
-
11. Volatile fatty acid findings in vaginal fluid compared with symptoms, signs, other laboratory results, and susceptibility to tinidazole of malodorous vaginal discharges.
The relevance of volatile fatty acids as a diagnostic test in 79 women with abnormal vaginal discharge was evaluated by a blind, randomised, and placebo controlled trial of tinidazole as a single oral 2 g dose. Automated gas chromatography of ether extracts of discharges taken before treatment showed volatile fatty acids in 18. Volatile fatty acids correlate
-
12. Anaerobic Wound Infections in Cancer Patients: Comparative Trial of Clindamycin, Tinidazole, and Doxycycline
Clindamycin, tinidazole (a parent compound to metronidazole), and doxycycline were compared in vitro against 376 anaerobic bacteria isolated from clinical specimens. Bacteriostatic tests indicated that clindamycin was the most active drug, on a weight basis, against these strains except for Clostridium species. The three drugs were compared as therapies for